Repare Therapeutics discloses employment terms for CAO Sandra Alves: CA$350k salary, 35% bonus target

Repare Therapeutics Inc.

Annual base salary: CA$350,000; target annual cash bonus: 35% of base salary.
Non-change-in-control severance: 7 months' salary, benefits continuation, 6-month vesting acceleration.
Change-in-control severance: lump sum of base salary plus higher of target or prior year bonus, 12 months benefits, full vesting.
Employment agreement entered May 28, 2025, effective with Ms. Alves' appointment as CAO.
Agreement will be filed with Q2 2025 Form 10-Q.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sandra Alves

Senior Vice President, Chief Accounting Officer and principal accounting officer

Repare Therapeutics Inc.

Filed: June 2, 2025, 7:59 PM ET

In connection with Ms. Alves’ appointment as the Company’s Senior Vice President, Chief Accounting Officer and principal accounting officer, the Company entered into an employment agreement with Ms. Alves on May 28, 2025 (the “ Employment Agreement ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sandra Alves was appointed as Senior Vice President, Chief Accounting Officer and principal accounting officer at Repare Therapeutics Inc..

Action: appointed
Role: Senior Vice President, Chief Accounting Officer and principal accounting officer

Exact text from the filing

In connection with Ms. Alves’ appointment as the Company’s Senior Vice President, Chief Accounting Officer and principal accounting officer, the Company entered into an employment agreement with Ms. Alves on May 28, 2025 (the “ Employment Agreement ”).

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-25-133312

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.